Exclusive: Vertex drops AAV gene therapy research, tRNA therapy partnership

on

Title

Vertex Exits AAV Gene Therapy and tRNA Partnership, Marking Major Shift in Genetic Medicine Strategy

Keywords

  • Vertex Pharmaceuticals
  • AAV gene therapy
  • tRNA therapy
  • Affinia Therapeutics
  • Tevard Biosciences
  • gene therapy market
  • cell and gene therapy
  • biotech pipeline
  • regulatory challenges
  • industry trends

Key Facts

  • Vertex Pharmaceuticals has discontinued all research and development involving adeno-associated virus (AAV) gene therapy technology, a pivotal move away from what was once considered a cornerstone of genetic medicine235.
  • The strategic retreat includes ending partnerships with Affinia Therapeutics (focused on AAV technology) and Tevard Biosciences (focused on transfer RNA, or tRNA, therapy)35.
  • This decision mirrors a broader industry trend, as other biotech giants like Pfizer have also recently withdrawn AAV-based therapies due to safety concerns and regulatory headwinds. Pfizer notably pulled its hemophilia B gene therapy Beqvez from the market in March 20253.
  • The move signals a significant shift in the gene therapy sector, which has seen more than $50 billion in investment since 2018 but is now facing increased scrutiny over safety, regulatory changes, and diminished investor enthusiasm3.
  • The SPDR S&P Biotech ETF, a key industry benchmark, has dropped 14% year-to-date, reflecting waning confidence in viral vector-dependent biotech companies after several high-profile program discontinuations3.
  • Vertex's exit underscores a turning point in gene therapy, marking what some analysts call "the year gene therapy hype finally collides with operational reality," and is prompting other companies to reassess the viability of similar therapeutic platforms3.
  • The discontinuation adds to other recent setbacks for Vertex, including shelving of early-stage candidates in unrelated therapeutic areas4.

This development represents both a strategic repositioning for Vertex and an inflection point for the entire gene therapy landscape, as companies and investors adjust to new safety, regulatory, and economic realities.

Sources:

2. https://www.trialsitenews.com/a/vertex-pharmaceutical-discontinues-aav-gene-therapy-researchpart-of-a-trend-3f6c9a83

3. https://www.ctol.digital/news/biotech-gene-therapy-vertex-safety-regulations/

4. https://www.biospace.com/business/vertex-scraps-two-phase-i-aatd-candidates-following-disappointing-data

5. https://endpts.com/news/